AMRX Amneal Pharmaceuticals Forecast, Technical & Fundamental Analysis

AMRX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 10, 2026

AMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 17 of 20 cases where AMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in 245 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 216 of 258 cases where AMRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRX as a result. In 64 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

AMRX moved below its 50-day moving average on September 04, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AMRX crossed bearishly below the 50-day moving average on September 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (178.571) is normal, around the industry mean (46.728). P/E Ratio (35.438) is within average values for comparable stocks, (93.360). AMRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). AMRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.787) is also within normal values, averaging (176.516).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.